Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525934 | 0.89 | CYSLTR2 (0.39) | CYSLTR2CYSLTR1PDE3BPDE3AP2RY12 | |
| SCHEMBL525953 | 0.87 | CYSLTR2 (0.38) | CYSLTR2CYSLTR1PDE3BPDE3AP2RY12 | |
| SCHEMBL525626 | 0.84 | PDE3B (0.34) | PDE3BPDE3AP2RY12LTA4HPPARG | |
| SCHEMBL18900347 | 0.82 | LTA4H (0.46) | CYSLTR2CYSLTR1PDE3BPDE3AP2RY12 | |
| SCHEMBL18899637 | 0.82 | CYSLTR2 (0.35) | CYSLTR2CYSLTR1PDE3BPDE3AP2RY12 | |
| SCHEMBL14973527 | 0.80 | PDE3B (0.38) | PDE3BPDE3AP2RY12LTA4HPPARG | |
| SCHEMBL525916 | 0.79 | PDE3B (0.39) | CYSLTR2CYSLTR1PDE3BPDE3AP2RY12 | |
| SCHEMBL530477 | 0.77 | PDE3B (0.30) | PDE3BPDE3AP2RY12 | |
| SCHEMBL14973639 | 0.77 | PDE3B (0.34) | CYSLTR2CYSLTR1PDE3BPDE3AP2RY12 | |
| SCHEMBL16770360 | 0.74 | CYSLTR2 (0.33) | CYSLTR2CYSLTR1PDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| EP-2598507-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, TP53, MYC | CYSLTR2 4700/4885CYSLTR1 4699/4885PDE3B 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.